Please ensure Javascript is enabled for purposes of website accessibility

Why Karyopharm Therapeutics Inc Stock Gained 16.4% in March

By Cory Renauer – Apr 7, 2017 at 10:07AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It was an exciting month of ups and downs for the biotech and its blood-cancer candidate.

What happened

Last month's roller-coaster ride for Karyopharm Therapeutics Inc (KPTI 1.60%) stock ended on a high note. Shares rose 16.4% in March, according to data from S&P Global Market Intelligence. It was an eventful month for the clinical-stage biotech and its lead treatment candidate.

So what 

March came in like a lion for Karyopharm's blood cancer hopeful. Selinexor is a first-in-class oral treatment slated for a large, late-stage combination study with multiple myeloma patients also receiving Velcade and standard chemo. If successful, results from the pivotal trial could eventually support the company's first New Drug Application, which would send the stock rising.

Pills stacked on bills in the shape of a chart sloping upwards.

Image source: Getty Images.

Last month, the company announced a clinical trial failure with selinexor, as a solo treatment of acute myeloid leukemia. About a week later, disaster struck in the form of an Food and Drug Administration clinical hold for the candidate.

Now what

Although clinical holds often derail clinical-stage programs, Karyopharm quickly emerged relatively undamaged. The FDA limited the hold to new patients while allowing those already on the drug to continue as the company submitted some missing info responsible for the hold.

The company expects the brief pause in new patient dosings won't change solinexor's overall development timeline. Investors will want to keep an eye out for a start to its pivotal multiple myeloma trial. Further out, a myeloma combo treatment trial with selinexor and Darzalex could lift the stock by year's end.

While the multiple myeloma space is getting somewhat crowded, the drug's unique function could help it carve out a niche among myeloma patients that have relapsed following treatment with available drugs.

Cory Renauer has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.